Jeevan Scientific Technology Limited has successfully completed its Rs 30.74 crore capital raising plan through the allotment of convertible warrants and equity shares. The company's board meeting held on January 2, 2026, approved the allotment of securities to promoters and non-promoters following BSE's in-principle approval.

Major Stake Acquisition by Padmaja Private Trust

In a significant development, Padmaja Private Trust has acquired a substantial 7.53% stake in the company through the recent preferential allotment. The acquisition details are as follows:

This acquisition triggered disclosure requirements under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as Padmaja Private Trust crossed the substantial acquisition threshold.

SEBI Regulatory Compliance

Following the acquisition, Padmaja Private Trust has filed the mandatory disclosure under Regulation 29(1) of SEBI regulations on January 5, 2026. The filing confirms the acquisition details and provides comprehensive information about the trust's holdings:

Complete Allotment Details

The board has successfully allotted the planned securities as outlined in their earlier proposal:

The allotment was completed pursuant to BSE's in-principle approval granted through Letter Reference No. LOD/PREF/HC/FIP/1377/2025-26 dated December 18, 2025.

Updated Capital Structure

Following the allotment, the company's equity capital structure has been revised:

Fund Utilization and Strategic Plans

The funds raised will be utilized for:

This successful capital raise and the entry of Padmaja Private Trust as a substantial investor strengthens Jeevan Scientific Technology's financial position and provides the necessary resources for its planned expansion in the healthcare sector, including potential acquisitions and capacity enhancement initiatives.

Jeevan Scientific Technology Limited (JSTL) has announced a significant capital raising initiative, as approved by its Board of Directors on October 15, 2025. The company plans to raise approximately Rs. 30.74 crore through a combination of convertible warrants and equity share issuances.

Key Highlights of the Capital Raising Plan

1. Convertible Warrants Issue:

   • Up to 35,00,000 convertible warrants to be issued
   • Issue price: Rs. 40.00 per warrant
   • Total amount to be raised: Rs. 14.00 crore
   • Allotted to both promoters and non-promoters

2. Equity Shares Issue:

   • Up to 41,85,000 equity shares to be issued
   • Issue price: Rs. 40.00 per share
   • Total amount to be raised: Rs. 16.74 crore
   • Allotted exclusively to non-promoters

Detailed Breakdown of the Proposed Allotment

Convertible Warrants Allotment

Top Equity Shares Allottees (Non-Promoters)

Additional Corporate Actions

1. Increase in Authorized Share Capital:

   • From Rs. 21.00 crore to Rs. 25.00 crore
   • New structure: 2,50,00,000 equity shares of Rs. 10.00 each

2. Adoption of New Memorandum of Association:

   • To align with the Companies Act, 2013

3. Committee Reconstitution:

   • Audit, Nomination and Remuneration, Stakeholder Relationship, Risk Management, and Corporate Social Responsibility committees have been reconstituted

Shareholder Approval and Regulatory Compliance

• An Extraordinary General Meeting (EGM) is scheduled for November 12, 2025, to seek shareholder approval for these proposals
• The preferential allotment is subject to regulatory approvals

Impact on Shareholding Pattern

Post-allotment, assuming full subscription and conversion of warrants:

• Promoters' holding: 90,24,585 equity shares (38.37%)
• Public holding: 1,44,94,380 equity shares (61.63%)

This capital raising initiative by Jeevan Scientific Technology Limited represents a strategic move to strengthen its financial position. The company's decision to offer a significant portion of the new securities to non-promoters could potentially lead to a more diverse shareholder base. Investors and market watchers will be keenly observing the outcome of the upcoming EGM and the subsequent steps in this capital raising process.